LAVAL, QC, March 10, 2017 /CNW Telbec/ - With the
support of Ergoresearch, Équilibre—the largest network of
orthotists in Quebec, announces
the adoption of the latest cutting-edge technology in the
management of knee pain: KneeKGTM, which expands
the evaluation services it offers in its clinics and knee
centres.
With the goal of providing an effective, personalized plan of
treatment, Équilibre now provides complete and precise diagnostic
evaluation services for the knee. This unique approach is made
possible by KneeKG™ technology, which measures objective,
standardized data while the patient is in movement.
"KneeKGTM represents a real revolution in the
examination of the knee, as the precision of the technology permits
the optimization of the plan of treatment. This means that the
patient gains better quality of life and is able to be more mobile,
which fully aligns with our mission", says Sylvain Boucher, President and CEO of
Ergoresearch.
The data gathered by KneeKGTM provide the basis for
an interdisciplinary approach with specialists from Équilibre
(kinesiologists, physical readaptation technicians, orthotists), as
well as the treating physician, physiotherapists, and other
Quebec healthcare
professionals.
KneeKGTM was created in 2007 and is the result of 12
years of research at 3 universities in Quebec (École de Technologie Supérieure,
centre de recherché du CHUM at Université de Montréal, and École
Polytechnique) and the company Emovi. This system for the 3D
analysis of anomalies of the knee received important support from
the international medical community which benefits significantly
from the new technology. In Quebec, Dr Pierre
Ranger, orthopedic surgeon and chief of the orthopedic
department at Jean-Talon hospital says: "The advantage of this
technology is that it helps us diagnose problems of the knee and
gives us relevant information to establish a plan of treatment and
follow patients once they implement the plan."
Emovi, the Quebec-based company
that markets KneeKGTM technology, is enthusiastic about
the new partnership. "We are very pleased with our collaboration
with Équilibre and its impressive network of clinics that will
provide greater access to this examination tool throughout
Quebec" mentions Alexandre Fuentes, vice-president for clinical
affairs at Emovi.
A new program, "I'm taking care of my arthrosis", which
accompanies KneeKGTM will be spearheaded in Quebec by Ergoresearch who, while implementing
the new technology, will also provide complete multidisciplinary
care including therapist-supervised and personalized exercise
programs.
This program is unique in Quebec and is grounded in the physical
participation of each patient in their therapy. "We are proud to be
able to contribute to the growth of Quebec-designed technology and to promote an
interdisciplinary approach within our organization—and all this,
with the goal of providing our patients with the best possible
quality of life", adds Mr. Boucher.
About Ergoresearch
Ergoresearch is a Canadian company that designs and manufactures
cutting edge technologies and solutions for the orthopedic
industry. The company is listed on the Toronto Stock Exchange and
trades under the symbol "ERG". With a portfolio of patents
relating to orthopedics and human bionics, the company is a
leader in the creation of custom-made orthotic devices.
Ergoresearch has also developed the most influential network of
orthotist clinics in Quebec, under
the banner "Équilibre", with over 70 clinics and points of service
throughout Quebec.
About Équilibre
Équilibre—orthotic devices ("braces") and biomechanics, is
the largest network of orthotists in Quebec, which provides a host of biomechanic
device solutions. Driven by wide-ranging innovation and the
expertise of healthcare professionals, Équilibre's mission is to
get people moving by reducing pain, rehabilitating motor functions
and optimizing performance. Thanks to its 70 clinics and points of
service, Équilibre is now found in all corners of Quebec.
About Emovi
Emovi is a Quebec company that
provides medical solutions for the knee articulation. With partners
in university research centres throughout Quebec, including the CRCHUM and École de
technologie supérieure (ÉTS),
Emovi developed KneeKGTM which identifies
biomechanical deficiencies that cause pain and disabilities.
This new technology has already provided relief to a large
number of patients suffering from pathologies of the knee including
arthrosis, meniscal tear and torn ligaments, patellofemoral
syndrome, tendinitis, etc. KneeKGTM is now available in
Canada, the US, France, Switzerland, China and Australia.
This communication does not aim to encourage the purchase
of shares on the Toronto Stock Exchange. Neither TMX Group Limited
nor any of its affiliated companies endorses or recommend the
shares in question. Please obtain the advice of a specialist to
evaluate specific shares.
SOURCE Ergoresearch Ltd